Endometrial CancerNCT07739745
Development Of An Endometrial Cancer Educational Tool
A study testing Interactive Educational Website in people with Endometrial Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The goal of this study is to develop an online educational tool that we can make widely available to broader patient community. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Endometrial Cancer
- What is being tested?
- Interactive Educational Website
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2027to 1 Jun 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients:
- Study Objective 1 (Part A-C see Figure 2)
- Women who have been diagnosed with endometrial cancer
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must provide written informed consent
Show all 21Show fewer
- Study Objectives 2 and 3 (Pilot Study)
- Women who have been diagnosed with endometrial cancer who are or will be receiving systemic treatment
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must provide written informed consent.
- Physicians:
- Study Objective 1 (Qualitative Interviews)
- Gynecologic oncologists or medical oncologists who practice at MDA or outside institutions
- Must be able to speak and read English
- Must provide written informed consent
- Healthcare Providers:
- Study Objectives 2 and 3 (Pilot Study)
- Healthcare Providers (including but not limited to gynecologic oncologists and APPs) who practice at MDA, the HALs or LBJ Hospital who provide care to women diagnosed with endometrial cancer
- Must be able to speak and read English
- Must provide written informed consent
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
UT MD Anderson
Houston, Texas, 77030
Larissa Meyer, MD, MPH, 713-745-0973, lmeyer@mdanderson.org
Larissa Meyer, MD, MPH
About this study
The goal of this study is to develop an online educational tool that we can make widely available to broader patient community.
Read the detailed description
Primary Objectives:
- To develop an EC educational tool for systemic therapy of endometrial cancer.
- To explore:
- Acceptability of incorporating the EC educational tool into routine clinical care through a pilot study with EC patients
- Feasibility, acceptability and the appropriateness of incorporating the EC educational tool into routine clinical care through a pilot study with health care providers of EC patients
- To estimate the effectiveness of the EC educational tool with EC patients through a pilot study of EC patients and their health care providers.
- Conditions
- Endometrial Cancer
- Being tested
- Interactive Educational Website
- Medical subject headings
- Endometrial Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Interactive Educational WebsiteOther
Participants will utilize website to access educational content, knowledge measure, values survey, and cognitive and usability testing
| Study group | Role | What they receive |
|---|---|---|
| Healthcare Providers | Experimental | Healthcare providers will be recruited from MD Anderson Cancer Center and outside institutions to reflect a broad group of physicians Receives: Other: Interactive Educational Website |
| Patients | Experimental | Participants will be recruited from the University of Texas MD Anderson Cancer Center (MDA), MDA Houston Area Locations (HALs), and The Harris Health System (LBJ). Receives: Other: Interactive Educational Website |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start1 Jan 2027 (estimated)
- Primary completion1 Jun 2030 (estimated)
- Study completion1 Jun 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Endometrial CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Larissa Meyer, MD, MPH, Principal investigator, UT MD Anderson
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07739745
- Sponsor's protocol ID
- 2025-0421
- Other IDs
- NCI-2026-05749
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development Of An Endometrial Cancer Educational Tool
- ClinicalTrials.gov ID
- NCT07739745
- Acronym / sponsor ID
- 2025-0421
- Conditions
- Endometrial Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 1 Jan 2027 (estimated)
- Primary completion
- 1 Jun 2030 (estimated)
- Study completion
- 1 Jun 2032 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to develop an online educational tool that we can make widely available to broader patient community.
Detailed description
Primary Objectives:
- To develop an EC educational tool for systemic therapy of endometrial cancer.
- To explore:
- Acceptability of incorporating the EC educational tool into routine clinical care through a pilot study with EC patients
- Feasibility, acceptability and the appropriateness of incorporating the EC educational tool into routine clinical care through a pilot study with health care providers of EC patients
- To estimate the effectiveness of the EC educational tool with EC patients through a pilot study of EC patients and their health care providers.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthcare Providers | Experimental | Other: Interactive Educational WebsiteHealthcare providers will be recruited from MD Anderson Cancer Center and outside institutions to reflect a broad group of physicians |
| Patients | Experimental | Other: Interactive Educational WebsiteParticipants will be recruited from the University of Texas MD Anderson Cancer Center (MDA), MDA Houston Area Locations (HALs), and The Harris Health System (LBJ). |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (21 listed)
- Study Objective 1 (Part A-C see Figure 2)
- Women who have been diagnosed with endometrial cancer
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must provide written informed consent
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interactive Educational WebsiteParticipants will utilize website to access educational content, knowledge measure, values survey, and cognitive and usability testing | Other | Healthcare Providers, Patients |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
- UT MD Anderson WebsiteLink provided by the sponsor.
Related trials for Endometrial Cancer
RecruitingPhase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Active, not recruitingPhase 3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
Endometrial Neoplasms
RecruitingObservational study
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Endometrial Cancer, Cervical Cancer
RecruitingPhase 1/2
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Endometrial Cancer, Cancer of Endometrium
RecruitingPhase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Solid Tumor, Advanced Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Larissa Meyer, MD, MPH principal investigator
UT MD Anderson
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Interactive Educational Website in people with Endometrial Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Larissa Meyer, MD, MPH ((713) 745-0973, lmeyer@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.